Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Switching to a Dolutegravir-Rilpivirine Regimen
- SWORD-1 and SWORD-2 trials demonstrated that switching virologically suppressed patients from various regimens to once-daily oral dolutegravir plus rilpivirine was well tolerated and noninferior to continuing baseline therapy at Week 48[Llibre 2018]
- TANGO study showed comparable virologic efficacy of switching to dolutegravir/lamivudine vs continued tenofovir AF–based 3-drug or 4-drug ART[van Wyk 2020]
- Efficacy comparable across variety of subgroups
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies